Wedelolactone pharmaceutical use

A technology of wedelolide and its use, which is applied in the field of pharmaceutical use of wedelolide, and can solve the problems that there are no reports of drugs for angiogenesis, intimal hyperplasia, etc.

Inactive Publication Date: 2016-04-20
XIAMEN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of wedelolide in the preparation of drugs for inhibiting angiogenesis and intimal hyperplasia has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Wedelolactone pharmaceutical use
  • Wedelolactone pharmaceutical use
  • Wedelolactone pharmaceutical use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Inhibitory effect of wedelolide on neovascular neointimal hyperplasia and atherosclerosis in rats caused by balloon injury

[0033] The rat model of neointimal hyperplasia and atherosclerosis caused by balloon injury was used to observe the effect of wedelolide on the neointimal hyperplasia of the common carotid artery on the injured side of the model rats.

[0034] The specific method steps of the experiment are as follows:

[0035] 1) Experimental animals and reagents

[0036] 40 rats, male, with an average weight of 240-260 g, were purchased from the Experimental Animal Center of Xiamen University.

[0037] Wedelide was purchased from Shanghai Yuanye Biotechnology Co., Ltd.

[0038] 2) Animal handling methods

[0039] Rat feeding environment: temperature 23±1°C, humidity: 40%-60%, natural light, free drinking water, free eating. After 1 week of adaptation, they were randomly divided into 5 groups with 8 rats in each group, which were respectively record...

Embodiment 2

[0056] Example 2 Wedelolide inhibits the proliferation and migration of vascular smooth muscle cells (VSMC) cultured in vitro

[0057] The primary cultured rat thoracic aortic vascular smooth muscle cells were stimulated with platelet-derived growth factor (PDGF) to proliferate and migrate, and the inhibitory effect of wedelolide on PDGF-induced vascular smooth muscle cell proliferation and migration was observed.

[0058] The specific method steps of the experiment are as follows:

[0059] 1) Primary cell culture:

[0060] Rats, male, 130-150 g, were purchased from the Experimental Animal Center of Xiamen University.

[0061] After chloral hydrate anesthetizes the rat, make a median chest incision, separate the thoracic aorta, wash it in PBS, cut it into small pieces, and paste it on a petri dish. After it is firmly attached, add DMEM medium containing 20% ​​FBS for culture , change the medium for about 3 days, and subculture after a certain number of cells climb out. Pass...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses wedelolactone pharmaceutical use, especially wedelolactone pharmaceutical use in manufacture of drugs to inhibit vascular neointimal hyperplasia and resist atherosclerosis, wedelolactone has the effect to inhibit the vascular neointimal hyperplasia, and the effect to inhibit the vascular neointimal hyperplasia is achieved mainly through the inhibition of proliferation and migration of vascular smooth muscle cells. The wedelolactone pharmaceutical use provides a research idea for use of the wedelolactone in manufacture of the drugs to inhibit the vascular neointimal hyperplasia and resist the atherosclerosis, and is expected to be applied to coronary angioplasty, stent implantation and other operation and prevention and treatment of the vascular neointimal hyperplasia and resist the atherosclerosis caused by improper diets and other reasons.

Description

technical field [0001] The invention relates to the pharmaceutical application of wedelolide, especially the application in the preparation of drugs for inhibiting angiogenesis and intimal hyperplasia and anti-atherosclerosis drugs. Background technique [0002] Coronary artery bypass grafting, heart stent and other operations are widely used in the world because they can effectively relieve symptoms such as angina pectoris and myocardial infarction in patients with coronary atherosclerotic heart disease and prolong life. Injury, vascular smooth muscle cell (vascular smooth muscle cell, VSMC) proliferation and migration and accumulation of extracellular matrix lead to angiogenesis, intimal hyperplasia, and subsequent atherosclerosis. The vascular stenosis caused by this process seriously affects the long-term efficacy. The abnormal proliferation and migration of VSMC is the main cause of vascular disease, which directly leads to the occurrence of neovascular neointimal hyper...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/37A61P9/10
Inventor 金鑫赵云彭璐景佐
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap